...
首页> 外文期刊>American Journal of Pathology: Official Publication of the American Association of Pathologists >Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.
【24h】

Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.

机译:癌细胞表达podoplanin导致肿瘤淋巴管生成和转移至淋巴结。

获取原文
获取原文并翻译 | 示例

摘要

The membrane glycoprotein podoplanin is expressed by several types of human cancers and might be associated with their malignant progression. Its exact biological function and molecular targets are unclear, however. Here, we assessed the relevance of tumor cell expression of podoplanin in cancer metastasis to lymph nodes, using a human MCF7 breast carcinoma xenograft model. We found that podoplanin expression promoted tumor cell motility in vitro and, unexpectedly, increased tumor lymphangiogenesis and metastasis to regional lymph nodes in vivo, without promoting primary tumor growth. Importantly, high cancer cell expression levels of podoplanin correlated with lymph node metastasis and reduced survival times in a large cohort of 252 oral squamous cell carcinoma patients. Based on comparative transcriptional profiling of tumor xenografts, we identified endothelin-1, villin-1, and tenascin-C as potential mediators of podoplanin-induced tumor lymphangiogenesis and metastasis. These unexpected findings identify a novel mechanism of tumor lymphangiogenesis and metastasis induced by cancer cell expression of podoplanin, suggesting that reagents designed to interfere with podoplanin function might be developed as therapeutics for patients with advanced cancer.
机译:膜糖蛋白podoplanin由几种类型的人类癌症表达,可能与其恶性进展有关。然而,其确切的生物学功能和分子靶标尚不清楚。在这里,我们使用人MCF7乳腺癌异种移植模型评估了podoplanin在转移癌中的肿瘤细胞表达与淋巴结的相关性。我们发现,podoplanin表达促进体外肿瘤细胞运动,出乎意料的是,在体内不增加原发性肿瘤生长的情况下,却增加了肿瘤淋巴管生成和向局部淋巴结的转移。重要的是,在252名口腔鳞状细胞癌患者中,podoplanin的高癌细胞表达水平与淋巴结转移和生存时间缩短相关。基于比较的肿瘤异种移植的转录谱,我们确定内皮素-1,villin-1和腱生蛋白C是podoplanin诱导的肿瘤淋巴管生成和转移的潜在介质。这些出乎意料的发现确定了由podoplanin的癌细胞表达诱导的肿瘤淋巴血管生成和转移的新机制,这表明设计用于干扰podoplanin功能的试剂可能被开发为晚期癌症患者的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号